Sumitomo Pharma Co., Ltd. (4506) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Sumitomo Pharma Co., Ltd.

Why is Sumitomo Pharma Co., Ltd. ?

With a growth in Net Profit of 364.02%, the company declared Outstanding results in Jun 25

The company has declared positive results for the last 2 consecutive quarters
OPERATING CASH FLOW(Y) Highest at JPY 41,361 MM
NET SALES(HY) At JPY 213,651 MM has Grown at 25.53%
ROCE(HY) Highest at 11.22%

With ROE of 13.95%, it has a attractive valuation with a 1.92 Price to Book Value

Over the past year, while the stock has generated a return of 277.61%, its profits have risen by 117.8% ; the PEG ratio of the company is 0.1
At the current price, the company has a high dividend yield of 0.1

Market Beating performance in long term as well as near term

Along with generating 277.61% returns in the last 1 year, the stock has outperformed Japan Nikkei 225 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Sumitomo Pharma Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Sumitomo Pharma Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Sumitomo Pharma Co., Ltd.

277.61%

183.79

73.64%

Japan Nikkei 225

28.54%

1.11

25.75%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-3.75%

EBIT Growth (5y)

-15.63%

EBIT to Interest (avg)

-8.65

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

1.67

Sales to Capital Employed (avg)

0.65

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.01%

ROCE (avg)

3.30%

ROE (avg)

4.62%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.92

EV to EBIT

40.70

EV to EBITDA

15.00

EV to Capital Employed

1.34

EV to Sales

1.52

PEG Ratio

0.12

Dividend Yield

0.12%

ROCE (Latest)

3.30%

ROE (Latest)

13.95%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

25What is working for the Company

OPERATING CASH FLOW(Y)

Highest at JPY 41,361 MM

NET SALES(HY)

At JPY 213,651 MM has Grown at 25.53%

ROCE(HY)

Highest at 11.22%

PRE-TAX PROFIT(Q)

At JPY 11,932 MM has Grown at 171.01%

INVENTORY TURNOVER RATIO(HY)

Highest at 1.57%

DEBTORS TURNOVER RATIO(HY)

Highest at 4.71%

OPERATING PROFIT MARGIN(Q)

Highest at 23.39 %

NET PROFIT(Q)

At JPY 11,206 MM has Grown at 89.66%

-11What is not working for the Company

INTEREST(Q)

At JPY 9,053 MM has Grown at 21.5%

CASH AND EQV(HY)

Lowest at JPY 43,569 MM

Here's what is working for Sumitomo Pharma Co., Ltd.

Pre-Tax Profit

At JPY 11,932 MM has Grown at 171.01%

over average net sales of the previous four periods of JPY 4,402.75 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (JPY MM)

Net Sales

At JPY 213,651 MM has Grown at 25.53%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (JPY MM)

Operating Cash Flow

Highest at JPY 41,361 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (JPY MM)

Operating Profit Margin

Highest at 23.39 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Net Profit

At JPY 11,206 MM has Grown at 89.66%

over average net sales of the previous four periods of JPY 5,908.5 MM

MOJO Watch

Near term Net Profit trend is positive

Net Profit (JPY MM)

Inventory Turnover Ratio

Highest at 1.57%

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Debtors Turnover Ratio

Highest at 4.71%

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Here's what is not working for Sumitomo Pharma Co., Ltd.

Interest

At JPY 9,053 MM has Grown at 21.5%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Cash and Eqv

Lowest at JPY 43,569 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents